Clinical Value of Adding Dapagliflozin in Patients with Nephrotic Syndrome

Abstract Background The nephrotic syndrome has one of the best-known presentations of adult and pediatric kidney disease. The incidence of nephrotic syndrome is approximately 2 to 4 new cases per 100,000 population per year. While advances had been made in the treatment of various glomerulonephritides, some uncertainty still exists regarding the management of nephrotic syndrome owing to the lack of high-quality randomized trials of treatment or interventions and systematic reviews. Aim of the Work to assess whether dapagliflozin compared with placebo reduces edema and proteinuria in patients with nephrotic syndrome. Additional exploratory endpoints include changes in eGFR and bodyweight. Patients and Methods The present study was a randomized controlled trial conducted to assess the clinical value of adding dapagliflozin to the standard of care in patients with nephrotic syndrome. Results A notable and statistically significant mean difference in baseline proteinuria was observed between the two study groups (3645.17 ± 928.1 mg/g; p